MedPath

Intraoperative Mitomycin C, Amniotic Membrane Transplantation and Conjunctival Autograft for Primary Pterygium

Not Applicable
Conditions
Pterygium
Registration Number
NCT02102776
Lead Sponsor
Sun Yat-sen University
Brief Summary

The purpose of this randomized multi-center clinical trial is to compare the efficacy and safety of intraoperative mitomycin C(MMC),amniotic membrane transplantation(AMT) and Conjunctival Autograft(CAG) for primary pterygium surgery. The investigators will also evaluate particular risk factors related to pterygium recurrence.

Detailed Description

Patients with primary pterygium will be randomly assigned to undertake pterygium excision followed by intraoperative mitomycin C application,amniotic membrane transplantation or conjunctival autograft in five clinical centers. Multi-center collaboration and quality monitoring will be based on a website designed for this study. The patients will be followed at least 12 months. Corneal Recurrence as the primary outcome measure, is considered as a fibrovascular ingrowth beyond the limbus with conjunctival drag.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
750
Inclusion Criteria
  • Primary pterygium
  • Willingness to participate in research project and to attend research follow-up
  • Adults (age 18 to 80 years old)
  • Patients must not meet any of the following exclusion criteria
Exclusion Criteria
  • Pregnant,breast-feeding women or patients with poor general health
  • Patients with significant ocular or lid pathology, such as Sjogren's Syndrome, infection, exposure keratitis, glaucoma, active uveitis, retinal detachment and trauma
  • Patients with previous surgery on ocular surface, such as trabeculectomy, strabismus surgery
  • Patients with allergy to intraoperative or postoperative drugs, such as mitomycin C, tobramycin or local anesthetics

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Recurrence of pterygiumOne year

Corneal Recurrence is considered as a fibrovascular ingrowth beyond the limbus with conjunctival drag

Secondary Outcome Measures
NameTimeMethod
Visual acuityOne year
Healing time of corneal epitheliumFour weeks
Healing time of conjunctival epitheliumFour weeks
Postoperative complicationsOne year

Trial Locations

Locations (5)

Zhongshan Ophthalmic Center, Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

Henan Provincial People's Hospital

🇨🇳

Zhengzhou, Henan, China

Xi'an Eye Hospital

🇨🇳

Xi'an, Shanxi, China

Sichuan Ganzi Autonomous Prefecture People's Hospital

🇨🇳

Ganzi, Sichuan, China

The Fourth Affiliated Hospital, Kunming Medical University

🇨🇳

Kunming, Yunnan, China

Zhongshan Ophthalmic Center, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Shiyou Zhou, M.D., Ph.D.
Principal Investigator
Tao Zhou, M.D.
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.